• Protocol digitization extracts structured data elements from unstructured text
• Automates database study builds, reducing build timelines by up to 30%
• Deployed within 40 study builds across Emmes CRO's portfolio of projects
• Future capabilities to include automated eCRF construction

ROCKVILLE, Md., Aug. 14, 2024 -- Veridix AI, part of Emmes Group, a specialty tech and AI enabled CRO, today announced the launch of their new protocol digitization capabilities. This advanced capability lays the foundation to accelerate the clinical trial study build process by up to 30%.

Built within Veridix AI's unified eClinical platform, Advantage eClinical Cloud, this new approach utilizes natural language processing (NLP) techniques in combination with AI, to digitize clinical trial protocols into structured data elements such as visit schedules, cohorts, and eCRFs. Trained and optimized from prior clinical trial data, the approach enables automated generation of visit schedules and provides a list of predicted eCRFs with 82%+ accuracy.

Clinical trial processes have been plagued by slow, manual, error-prone processes. Reviewing a protocol to determine elements required for study builds is no exception. This new approach presents a concrete application of AI techniques to accelerate clinical trials and improve data quality.

"Protocol digitization has the potential to reshape how protocol information is used throughout the clinical research process and ecosystem. Powered by NLP and AI technologies, we are automating more of the clinical trial process. This is just one example of how we're embedding more technology and AI within the clinical research process," said Rama Kondru, chief executive officer, Veridix AI.

Upcoming releases for Advantage eClinical Cloud will provide an embedded workflow for transforming protocols into structured data elements, and ultimately automated creation of eCRFs and associated edit checks based on AI predictions.

"This unique capability allows us to accelerate the study build process and allows our data managers to focus on value added work rather than manual, tedious processes," said Sastry Chilukuri, chief executive officer, Emmes Group. "We're already deploying this capability across more than 40 new study builds in both our government and commercial portfolio," added Chilukuri. "This highlights our commitment to improving clinical trials by applying next generation technology and AI capabilities."

About Emmes Group:

Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). The company is transforming the future of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Today, the company is transforming the future of clinical research, by creating the industry's first specialty, tech and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.

About Veridix AI:

Veridix AI is the technology and AI division of Emmes Group, dedicated to pioneering advancements in AI and patient-centric technologies. We are passionate about serving patients by bringing the latest technological and analytical advancements to clinical research. Through constant innovation we aim to increase the pace of clinical trials and help bring new treatments to patients more quickly. Combining our expertise with Emmes CRO's operational and scientific excellence, we are modernizing clinical research. Learn more at www.veridixai.com.

About Emmes CRO:

Emmes CRO, founded more than 45-years ago, is a global, full-service Clinical Research Organization dedicated to the advancement of public health and biopharmaceutical innovation. Emmes CRO has supported more than 2,000 clinical trials across numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. The company has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, and neuroscience. Today, we are part of the Emmes Group, helping transform the future of clinical research. Learn more at www.emmes.com.

Logo - https://mma.prnewswire.com/media/220594/Emmes_Group_Logo.jpg